The neurobiology of depression involves complex interactions among neurotransmitter systems, neural circuits, and inflammatory pathways. Standard antidepressants primarily target serotonin and norepinephrine, yet research shows that only about 50% of patients achieve remission after their first adequate medication trial, and response rates decline significantly with each subsequent attempt.
When standard medications fail, the underlying mechanisms often involve disruptions beyond simple neurotransmitter deficiency. Functional neuroimaging studies reveal that individuals with TRD frequently show altered connectivity in the dorsolateral prefrontal cortex and other mood-regulating brain regions, suggesting that the neural circuits governing emotional processing have become persistently dysregulated.
Genetic factors also play a substantial role. Variations in genes responsible for drug metabolism, receptor sensitivity, and neurotransmitter transport can make certain individuals biologically less responsive to conventional antidepressants. This pharmacogenomic variability means that what works for one patient may be fundamentally ineffective for another, regardless of dose or duration.
